$AEHR
AEHR TEST SYSTEMS Stock $aehr

$aehr Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000165495421011091 Filed on October 14, 2021

Income Statement

Concept	2021 Q3	2020 Q3
Revenue	$5.646M	$2.012M
YoY Change	180.62%	-63.62%
Cost Of Revenue	$3.365M	$1.785M
YoY Change	88.52%	-45.25%
Gross Profit	$2.281M	$227.0K
YoY Change	904.85%	-90.0%
Gross Profit Margin	40.4%	11.28%
Selling, General & Admin	$1.953M	$1.514M
YoY Change	29.0%	-16.35%
% of Gross Profit	85.62%	666.96%
Research & Development	$1.321M	$900.0K
YoY Change	46.78%	1.12%
% of Gross Profit	57.91%	396.48%
Depreciation & Amortization	$73.00K	$80.00K
YoY Change	-8.75%	-20.0%
% of Gross Profit	3.2%	35.24%
Operating Expenses	$3.274M	$2.414M
YoY Change	35.63%	-10.59%
Operating Profit	-$993.0K	-$2.187M
YoY Change	-54.6%	408.6%
Interest Expense	$9.000K	$13.00K
YoY Change	-30.77%	30.0%
% of Operating Profit
Other Income/Expense, Net	$23.00K	-$94.00K
YoY Change	-124.47%	-1040.0%
Pretax Income	$719.0K	-$108.0K
YoY Change	-765.74%	-73.66%
Income Tax	-$23.00K	$215.0K
% Of Pretax Income	-3.2%
Net Earnings	$696.0K	$107.0K
YoY Change	550.47%	-126.1%
Net Earnings / Revenue	12.33%	5.32%
Basic Earnings Per Share	$0.03	$0.00
Diluted Earnings Per Share	$0.03	$4.689K
COMMON SHARES
Basic Shares Outstanding	24.00K shares	23.25K shares
Diluted Shares Outstanding	25.36K shares	23.46K shares

Balance Sheet

Concept	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.530M	$6.310M
YoY Change	3.49%	19.73%
Cash & Equivalents	$6.530M	$6.393M
Short-Term Investments
Other Short-Term Assets	$759.0K	$440.0K
YoY Change	72.5%	-15.38%
Inventory	$10.15M	$8.100M
Prepaid Expenses
Receivables	$4.264M	$1.120M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$21.70M	$15.97M
YoY Change	35.87%	-12.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$676.0K	$2.570M
YoY Change	-73.7%	-27.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$189.0K	$150.0K
YoY Change	26.0%	-25.0%
Total Long-Term Assets	$2.302M	$2.720M
YoY Change	-15.37%	-27.27%
TOTAL ASSETS
Total Short-Term Assets	$21.70M	$15.97M
Total Long-Term Assets	$2.302M	$2.720M
Total Assets	$24.00M	$18.69M
YoY Change	28.42%	-15.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.753M	$810.0K
YoY Change	239.88%	-53.45%
Accrued Expenses	$1.978M	$2.040M
YoY Change	-3.04%	-6.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$930.0K
YoY Change	-100.0%
Total Short-Term Liabilities	$8.760M	$4.170M
YoY Change	110.07%	-8.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$750.0K
YoY Change	-100.0%
Other Long-Term Liabilities	$46.00K	$1.450M
YoY Change	-96.83%	-34.09%
Total Long-Term Liabilities	$46.00K	$2.200M
YoY Change	-97.91%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.760M	$4.170M
Total Long-Term Liabilities	$46.00K	$2.200M
Total Liabilities	$9.769M	$6.370M
YoY Change	53.36%	-5.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$75.62M
YoY Change
Common Stock	$245.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.23M	$12.32M
YoY Change
Total Liabilities & Shareholders Equity	$24.00M	$18.69M
YoY Change	28.42%	-15.16%

Cashflow Statement

Concept	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	$696.0K	$107.0K
YoY Change	550.47%	-126.1%
Depreciation, Depletion And Amortization	$73.00K	$80.00K
YoY Change	-8.75%	-20.0%
Cash From Operating Activities	$1.874M	$643.0K
YoY Change	191.45%	-438.42%
INVESTING ACTIVITIES
Capital Expenditures	$59.00K	$47.00K
YoY Change	25.53%	-194.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$59.00K	-$47.00K
YoY Change	25.53%	-6.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$135.0K	$190.0K
YoY Change	-28.95%	216.67%
NET CHANGE
Cash From Operating Activities	$1.874M	$643.0K
Cash From Investing Activities	-$59.00K	-$47.00K
Cash From Financing Activities	$135.0K	$190.0K
Net Change In Cash	$1.948M	$880.0K
YoY Change	121.36%	-588.89%
FREE CASH FLOW
Cash From Operating Activities	$1.874M	$643.0K
Capital Expenditures	$59.00K	$47.00K
Free Cash Flow	$1.815M	$596.0K
YoY Change	204.53%	-525.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26557065	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6530000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4582000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4264000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5202000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	10146000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	8849000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	759000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	551000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	21699000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	19184000	USD
CY2021Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	99000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	676000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	677000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1437000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1606000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	189000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	198000	USD
CY2021Q3	us-gaap	Assets Assets	24001000	USD
CY2021Q2	us-gaap	Assets Assets	21665000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2753000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2893000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1978000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2163000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	750000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	737000	USD
CY2021Q3	aehr	Customer Deposits And Deferred Revenue Short Term CustomerDepositsAndDeferredRevenueShortTerm	3279000	USD
CY2021Q2	aehr	Customer Deposits And Deferred Revenue Short Term CustomerDepositsAndDeferredRevenueShortTerm	189000	USD
CY2021Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	USD
CY2021Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1400000	USD
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2021Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1679000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8760000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9061000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	813000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1007000	USD
CY2021Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	150000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	46000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	49000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	9769000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	10216000	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24483000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23725000	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	245000	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	237000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89668000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87553000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-28000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75617000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76313000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	14232000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	11449000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24001000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21665000	USD
CY2021Q3	us-gaap	Revenues Revenues	5646000	USD
CY2020Q3	us-gaap	Revenues Revenues	2012000	USD
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	3365000	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	1785000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	2281000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	227000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1953000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1514000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1321000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	900000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	3274000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	2414000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-993000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2187000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	9000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	13000	USD
CY2021Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2020Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	2186000	USD
CY2021Q3	aehr	Gain From Forgiveness Of Ppp Loan GainFromForgivenessOfPppLoan	1698000	USD
CY2020Q3	aehr	Gain From Forgiveness Of Ppp Loan GainFromForgivenessOfPppLoan	0	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-94000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	719000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1535000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	588000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	696000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-36000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	14232000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	14056000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	696000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	107000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-108000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	215000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	696000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	107000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.03
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.00
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23999	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23248	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25356	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23455	shares
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-36000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-99000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	2401000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	660000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2195000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	21000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	660000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2216000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	11449000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	190000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	270000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	107000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	99000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	12321000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	696000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	107000	USD
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	588000	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	270000	USD
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	73000	USD
CY2020Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	82000	USD
CY2021Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2020Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	2186000	USD
CY2021Q3	aehr	Income Tax Benefit Related To Dissolution Of Subsidiary IncomeTaxBenefitRelatedToDissolutionOfSubsidiary	0	USD
CY2020Q3	aehr	Income Tax Benefit Related To Dissolution Of Subsidiary IncomeTaxBenefitRelatedToDissolutionOfSubsidiary	-215000	USD
CY2021Q3	aehr	Gain From Forgiveness Of Ppp Loan GainFromForgivenessOfPppLoan	1698000	USD
CY2020Q3	aehr	Gain From Forgiveness Of Ppp Loan GainFromForgivenessOfPppLoan	0	USD
CY2021Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	895000	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2642000	USD
CY2021Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1324000	USD
CY2020Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-112000	USD
CY2021Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-201000	USD
CY2020Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	80000	USD
CY2021Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-130000	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-59000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47000	USD
CY2021Q3	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1400000	USD
CY2020Q3	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2021Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1535000	USD
CY2020Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	190000	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	135000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	190000	USD
CY2021Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2000	USD
CY2020Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	94000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1948000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	880000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4662000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5513000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6610000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6393000	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-173000	USD
CY2021Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-169000	USD
CY2020Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-67000	USD
CY2021Q3	aehr	Increase Decrease In Customer Deposits And Deferred Revenue IncreaseDecreaseInCustomerDepositsAndDeferredRevenue	3141000	USD
CY2020Q3	aehr	Increase Decrease In Customer Deposits And Deferred Revenue IncreaseDecreaseInCustomerDepositsAndDeferredRevenue	214000	USD
CY2021Q3	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	3000	USD
CY2020Q3	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1000	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1874000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	643000	USD
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59000	USD
CY2020Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47000	USD
CY2021Q3	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">ACCOUNTING ESTIMATES. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used to account for sales and revenue allowances, the allowance for doubtful accounts, inventory valuations, income taxes, stock-based compensation expenses, and product warranties, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p>
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5646000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2012000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2021Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	119000	shares
CY2021Q3	aehr	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures1 StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures1	49000	shares
CY2021Q3	aehr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1	2.50
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	11000	shares
CY2020Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	161000	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	3000	shares
CY2021Q4	aehr	Gross Proceeds Before Commission Fee And Offering Expenses GrossProceedsBeforeCommissionFeeAndOfferingExpenses	25000000.0	USD
CY2021Q4	aehr	Net Proceeds After Commission Fee And Offering Expenses NetProceedsAfterCommissionFeeAndOfferingExpenses	24000000.0	USD

Files In Submission

Name	View Source	Status
0001654954-21-011091-index-headers.html	Edgar Link	pending
0001654954-21-011091-index.html	Edgar Link	pending
0001654954-21-011091.txt	Edgar Link	pending
0001654954-21-011091-xbrl.zip	Edgar Link	pending
aehr-20210831.xsd	Edgar Link	pending
aehr-20210831_cal.xml	Edgar Link	unprocessable
aehr-20210831_def.xml	Edgar Link	unprocessable
aehr-20210831_lab.xml	Edgar Link	unprocessable
aehr-20210831_pre.xml	Edgar Link	unprocessable
aehr_10q.htm	Edgar Link	pending
aehr_10q_htm.xml	Edgar Link	completed
aehr_ex311.htm	Edgar Link	pending
aehr_ex312.htm	Edgar Link	pending
aehr_ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AEHR
AEHR TEST SYSTEMS Stock $aehr

2021 Q3 Form 10-Q Financial Statement

#000165495421011091 Filed on October 14, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AEHR AEHR TEST SYSTEMS Stock $aehr

2021 Q3 Form 10-Q Financial Statement

#000165495421011091 Filed on October 14, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AEHR
AEHR TEST SYSTEMS Stock $aehr